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Background: Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) has been demonstrated to be an
important player in various human malignancies; it is thought to promote tumor growth by cell cycle regulating.
However, the roles of MALAT1 in esophageal squamous cell carcinoma(ESCC), and the mechanisms involved in cell
cycle regulation remain poorly understood. Moreover, the factors contributing to its up-regulation in tumor tissues
are still largely unclear.
Methods: Expression of MALAT1 was determined from cell lines and clinical samples by qRT-PCR. The effects of
MALAT1 knockdown on cell proliferation, cell cycle, apoptosis, migration, and invasion were evaluated by in vitro
and in vivo assays. The potential protein expression changes were investigated by Western-blotting. The methylation
status of the CpG island in the MALAT1 promoter was explored by bisulfite sequencing, while the copy numbers in
tumor tissues and blood samples were detected by a well-established AccuCopyTM method.
Results: MALAT1 was over-expressed in 46.3% of ESCC tissues, mostly in the high-stage tumor samples. Enhanced
MALAT1 expression levels were positively correlated with clinical stages, primary tumor size, and lymph node
metastasis. Inhibition of MALAT1 suppressed tumor proliferation in vitro and in vivo, as well as the migratory and
invasive capacity. MALAT1 depletion also induced G2/M phase arrest and increased the percentage of apoptotic
cells. Western-blotting results implicated that the ATM-CHK2 pathway which is associated with G2/M arrest was
phosphorylated by MALAT1 knockdown. No effects of CpG island methylation status on MALAT1 expression were
found, whereas amplification of MALAT1 was found in 22.2% of tumor tissues, which correlated significantly with
its over-expression. However, neither association between tissue copy number amplification and germline copy
number variation, nor correlation between germline copy number variation and ESCC risk were identified in the
case–control study.
Conclusions: Our data suggest that MALAT1 serves as an oncogene in ESCC, and it regulates ESCC growth by
modifying the ATM-CHK2 pathway. Moreover, amplification of MALAT1 in tumor tissues may play an important role for
its up-regulation, and it seems that the gene amplification in tumor tissues emerges during ESCC progression, but is
not derived from germline origins.
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Esophageal cancer is one of the leading aggressive malig-
nancies worldwide and ranks as one of the top five dead-
liest cancers in China, while squamous cell carcinoma
accounts for the most prevalent histopathologic type [1].
Despite the recent advances in ESCC treatment, the
prognosis of ESCC is still unfavorable [2,3], making it es-
sential for uncovering the underlying mechanisms of
ESCC for therapy improvement. The emerging roles of
lncRNAs in human tumorgenesis may hold great prom-
ise for understanding the carcinogenesis of ESCC [4].
Long noncoding RNA (lncRNA) is defined as a group
of RNAs (>200 nt) with limited or no coding capacity
due to a lack of an intact open reading frame, but par-
ticipates in most vital biological activities. LncRNAs
can affect gene expression via multiple fashions, in-
cluding chromatin reprogramming [5], X chromosome
inactivation [6], microRNA sponging [7], and so on. A
growing amount of literature has linked deregulation
of lncRNAs with diverse human cancers, such as the
well-characterized HOTAIR, MEG3, GAS5, H19, and
MALAT1 [8].
Metastasis Associated Lung Adencarcinoma Transcript
1 (MALAT1), mapped to human chromosome 11q13, was
originally identified as a prognostic marker for metastasis
and patient survival in NSCLC [9]. Following studies have
documented that MALAT1 was aberrantly up-regulated
in multiple cancerous tissues and conferred proliferative
and metastatic phenotypes to tumor cells [10-12]. It pro-
motes tumor growth and metastasis through different
mechanisms, including by recruiting SR family proteins
[13], binding to the active regions of chromosome [14],
and regulating alternative splicing of oncogenic mRNAs
[15], depending on tissue contexts. The role that it plays
in ESCC is of interest to our research group. Kuo et al.
reported that exogenous over-expression of tumor sup-
pressor gene sox17 impaired ESCC growth and mobil-
ity, with a synchronous decreased MALAT1 level [16],
which indirectly implicated that MALAT1 may serve as
an oncogene in ESCC.
There is a lot of evidence suggesting that MALAT1
may be involved in cell cycle regulation, which may
contribute to uncontrolled tumor growth. Its role in
G2/M regulation has been specifically emphasized
[15,17,18], but its detailed mechanism is still controver-
sial. Tripathi et al. reported that MALAT1 depletion
leads to an increased level of γH2AX (a DNA damage
indicator) and accumulated G2/M population, indicat-
ing a critical involvement of MALAT1 in genome
stability and cell cycle checkpoint. To our knowledge,
the tumor genomes are under frequent DNA damage
events and spontaneous genetic mutation, which could
activate the cell cycle checkpoints, represented by the
ATM-CHK2 pathway. The activated checkpoint mayprevent tumors from growing too quickly by inducing
cell cycle arrest. Inactivation of this checkpoint may re-
lease cells from cycle arrest, and results in accelerating
tumor growth. In consideration of the role of MALAT1 in
cell cycle progression and genome stability mainten-
ance, we speculated that MALAT1 could promote
ESCC proliferation by regulating the ATM-CHK2 path-
way, which is associated with DNA damage response
and the G2/M transition.
Moreover, the factors that lead to MALAT1 over-
expression in tumor tissues remain largely unknown,
previous studies have found that the expression level of
MALAT1 was controlled by methylation of histone H3
[19], transcriptional factors [16,20], and microRNAs
[21,22]; however, evidence to explain its over-expression
in diverse tumor tissues is lacking.
To better understand its roles in ESCC and the fac-
tors leading to its up-regulation, we investigated the
clinical significance of MALAT1 on ESCC and con-
firmed its biological functions by in vitro and in vivo
assays. We also checked the ATM-CHK2 pathway,
which is involved in DNA damage response and G2/M
arrest, to unravel the mechanisms by which MALAT1
regulates cell cycle progression and promotes ESCC
growth. To explore the factors contributing to its up-
regulation, we sequenced the CpG island located at its
promoter, and detected the copy number alterations
in tumor tissues. Finally, we determined whether the
MALAT1 amplification in tumor tissues was derived from
germline origins. We also evaluated the possibility that the
germline copy number variation (CNV) of MALAT1 be
used as an indicator of ESCC risk for Chinese Han people
in a case–control study.
Our results showed that MALAT1 was upregulated
mostly in late-stage tumor tissues, indicating that it
mainly functions in the advanced stages of ESCC but
not tumor initialization. Knockdown of MALAT1 sup-
pressed proliferation and metastasis of ESCC cells,
leading to G2/M arrest and an increased apoptosis ra-
tio. MALAT1 depletion activated the ATM-CHK2 path-
way, which should be responsible for G2/M arrest.
Our results also revealed a negative association between
MALAT1 expression and ATM-CHK2 pathway phosphor-
ylation in tumor tissues, suggesting that up-regulation of
MALAT1 may promote ESCC growth by dephosphoryla-
tion of the ATM-CHK2 pathway, which may loose the cell
cycle arrest. We also found that amplification of MALAT1
in tumor tissues may partially contribute to its over-
expression, but the genomic amplification in somatic
tissues should be a complex event, instead of being
derived from a germline source. In addition, the case–
control study results indicated that the germline CNV
of MALAT1 should not be treated as an indicator for
ESCC susceptibility.
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Tissue samples and cell lines
ESCC and corresponding normal esophageal epithelial tis-
sues were obtained from 54 patients who underwent sur-
gery resection during 2007–2012 at Southwest Hospital,
Chongqing, China. No patient recruited in the study re-
ceived radio- or chemo-therapy prior to surgery. Clinical
information was collected from medical records. All speci-
mens were snap-frozen and stored at −80°C until use. The
study was approved by the Research Ethics Committee of
the Third Military Medical University, Chongqing, China.
Written informed consent for biological research was
obtained from all participants.
Four esophageal squamous cell carcinoma cell lines
(EC109, EC9706, KYSE150, and KYSE450) were obtained
from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China) and Cancer Institute and Hospital,
Chinese Academy of Medical Sciences (Beijing, China). A
normal esophageal epithelial cell (Het-1A) was purchased
from Jenniobio Biotechnology (Guangzhou, China). All
cells were cultured in RPMI-1640 medium (Hyclone,
USA) supplemented with 10% fetal bovine serum (10%
FBS), and maintained in a humidified incubator at 37°C
with 5% CO2.
Case–control study population
A total of 201 cases diagnosed with ESCC and 193
ethnically-matched healthy controls were recruited
from Southwest Hospital. All subjects were genetically
unrelated ethnic Han-Chinese from southwest China.
The protocol and consent form were approved by the
Research Ethics Committee of the Third Military Med-
ical University. All participants provided informed con-
sent prior to enrollment.
Distribution of demographic characteristics are listed in
Additional file 1: Table S1.
RNA extraction and qRT-PCR
Total RNA was isolated from tissues and cell cultures with
Trizol reagent (Takara, Japan) according to the standard
protocol. The cDNA was synthesized from a total of
200 ng RNA using the PrimeScript RT reagent Kit
(Takara, Japan) and amplified by quantitative real-time
PCR with SYBR Green Kit (Takara, Japan) on Illumina
Eco™ (Illumina, USA). GAPDH was used as the internal
reference, and the relative expression level of MALAT1
was normalized to GAPDH.
Primers for MALAT1 and GAPDH are listed in
Additional file 2: Table S2.
DNA extraction
DNA was extracted from tumor tissues and blood sam-
ples using the Wizard® genomic DNA extraction Kit
(Promega, USA) according to the standard procedure,the extracted genomic DNA was dissolved in DNA rehy-
dration solution and stored at −20°C until use.
Small interfering RNA
Two small interfering RNAs (siRNAs) against MALAT1
(si-MALAT1) at different sites and one negative control
(si-NC) with no definite target were employed and syn-
thesized by GenePharma (Shanghai, China). Cells were
seeded on six-well plates at a density of 3 × 105/well
overnight, and then transfected with siRNA or the nega-
tive control at a final concentration of 100 nM using Li-
pofectamine 2000 (Invitrogen, USA). The interfering
efficiency was determined by qRT-PCR 48 h after trans-
fection, and the siRNAs with silencing efficacy of more
than 70% were selected for further experiments.
Sequences of siRNAs and negative control are pro-
vided in Additional file 3: Table S3.
Cell proliferation assay
Cells seeded on 96-well plates (5000/well) were trans-
fected with siRNAs or NC, and the cell proliferation as-
says were conducted every 24 h using cell counting kit8
(Djingo, Japan) as the manufacturer’s protocol. The
number of viable cells was quantified by the absorbance
of reduced WST-8 at 450 nm at indicated time points.
For colony forming experiments, cells (EC109 and
EC9706) transfected with siRNAs or NC were plated on
six-well plates at a density of 500/well, maintained in
RPMI-1640 medium containing 10% FBS for 12 days.
Medium was replaced every 3 days. Colonies were fixed
with methanol twelve days later and stained with 0.1%
crystal violet (Sigma, USA). Visible colonies were photo-
graphed and counted manually.
Flow-cytometric analysis of apoptosis and cell cycle
Cells seeded on six-well plates were harvested 72 h post
transfection by trypsin and collected by centrifugation.
Cell pellets were washed with cold PBS, and then fixed
in 70% ethanol at 4°C overnight. After fixation, the cells
were washed and resuspended in PBS, and then incu-
bated with ribonuclease at 37°C for 30 minutes, next
stained with propidium iodide (Beyotime, China) in the
dark at 4°C for 30 minutes, and finally analyzed by a
flow cytometer FACSCalibur (BD Bioscience, USA) and
Modlfit software (Verity Software House, USA).
For apoptosis analysis, the trypsinized and PBS washed
cells were stained with FITC-Annexin V and propidium
iodide (Beyotime, China). Cells were analyzed by FACS-
Calibur and Flowjo software (BD Bioscience, USA). Cells
were discriminated into viable cells, dead cells, early
apoptotic and late apoptotic cells, relative ratios of the
early and late apoptotic cells were compared to the con-
trol group.
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Cell migration and invasion assays were performed using
Costar chambers containing transwell inserts with a pore
size of 8 μm (Corning Incorporated, USA). The upper
chambers were either non-coated for migration or
coated with Matrigel (Invitrogen, USA) for the invasion
assay. Cells (5 × 104) transfected with siRNAs or NC
were suspended in 200 μl of serum-free medium and
seeded in the upper chamber, while the bottom chamber
contained medium mixed with 20% FBS. Thirty-six
hours after incubation, cells in the upper chamber were
removed by cotton swap, whereas the cells that had mi-
grated or invaded through the membrane were fixed
with methanol and stained with 0.1% crystal violet, im-
aged, and counted under an inverted microscope in five
random fields (Olympus, Japan).Tumor xenografts in nude mice
Four-week athymic female BALB/c mice were housed
and maintained in laminar airflow chambers under spe-
cific pathogen-free conditions. Lentiviral vectors for
si-MALAT1 and NC were separately constructed by
Genepharm, and the stably transfected EC109 cell lines
were established. The transfected EC109 cells were sus-
pended in PBS at a final concentration of 1 × 108 cells/ml
separately, a volume of 0.1 ml of suspended cells was sub-
cutaneously injected into a single side of the posterior
flank of each mouse (n = 5/group). At 21 days post in-
jection, the mice were sacrificed by cervical dislocation
in diethyl ether anesthesia, and the tumors were dissected
and weighed. The experimental protocols were approved
by the committee on animal experimentation of the Third
Military Medical University.Western blotting
Cells transfected with siRNAs or NC were lysed using
protein extraction reagent RIPA (Beyotime, China) 72 h
post transfection, supplemented with protease inhibitors
PMSF (Roche, Switzerland). ESCC tissues were ground
in homogenizers and proteins were extracted following
the manufacturer’s instructions (Beyotime, China). Half
of the ESCC tissues showed MALAT1 over-expression
and were higher than the mean expression level in ESCC,
while the other half didn’t. Equal amounts of protein
extractions were separated by 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), then transferred to polyviny-
lidene diflvoride membranes (Sigma, USA). The mem-
branes were blocked for 1 h at room temperature, and
subsequently incubated with specific primary antibodies
for 12 h. Then the membranes were washed three times
and incubated with the horseradish peroxidase (HRP)-con-
jugated secondary antibodies (anti-rabbit) for one hour.
ECL chromogenic substrate was used to visualize thebands. GAPDH was used as the control. Antibodies were
all purchased from Abcam (USA).
Methylation status analysis of CpG island
Genomic DNA prepared from ten pairs of ESCC and nor-
mal tissues was modified by sodium bisulfite using the EZ
DNA Methylation Kit (Zymo Research, USA), and then
amplified by PCR. PCR-amplified products were ligated to
pMD18-T vectors (TAKARA, Japan) and transformed into
E.coli DH5α cells. The LBamp+ agar/X-gal/IPTG plates were
used to select the qualified colonies. Ten colonies for each
sample were picked out and then cultured in LBamp+
medium overnight separately, and subsequently ob-
tained plasmids were subjected to sequencing.
Primers for CpG island amplification are available in
Additional file 2: Table S2.
Treatment of ESCC cells with demethylase 5-aza-cdR
EC109 and EC9706 cells (3 × 105) were plated on six-
well plates and grown overnight. After 24 h, the media
was removed and replaced with fresh media containing
0, 5, 10 μM of demethylase 5-aza-CdR (Sigma, USA).
The cells treated with 5-aza-CdR were harvested 48 h
post treatment and subjected to RNA extraction to de-
termine the MALAT1 expression level. To ensure that
the demethylation by 5-aza-CdR was actually occurring,
the CDH1 gene which was reported to be regulated by
CpG methylation in ESCC [23,24]. Primers for CDH1
are listed in Additional file 2: Table S2.
Copy number genotyping
Copy number of MALAT1 in tumor tissues and blood sam-
ples were interrogated by a custom-by-design AccuCopyTM
kit (Cat#: CN0105, Genesky Biotechnologies Inc, Shanghai,
China), which was developed based on a patented technol-
ogy from Genesky Biotechnologies Inc. The basic principal
of this method has been described previously [25], which
was based on a multiplex fluorescence competitive PCR, in
brief. To ensure the accuracy of copy number calculations,
four reference segments were utilized for normalization. A
probe targeted to MALAT1 (1500–1813 bp) was designed
for MALAT1 copy number detecting. The primers for the
MALAT1 probe and reference segments are provided in
Additional file 2: Table S2. Our data were produced mainly
according to the manufacturer’s manual.
Statistical analysis
Each biological experiment was performed in triplicate
and repeated three times. Data are shown as mean ±
standard deviation (SD). Statistical significance was tested
by Student’s t-test (two-tailed), Chi-square test and one-
way ANOVA analysis as appropriate. An unconditional lo-
gistic regression model was used to assess the associations
between MALAT1 copy number genotypes and ESCC risk
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status. All statistical analyses were performed on SPSS
16.0. P < 0.05 was considered as significant.
Results
MALAT1 expression was up-regulated predominantly in
advanced-stage ESCC tissues
qRT-PCR was used to detect MALAT1 expression levels
in cell lines and clinical samples, which were normalizedFigure 1 Relative MALAT1 expression in cell lines and tissues assesse
MALAT1 in ESCC cell lines (EC109, EC9706, KYSE450, and KYSE150) compa
presented as expression fold-change relative to Het-1A. (B) Over-expression o
MALAT1 was detected in 54 pairs of clinical samples and normalized to GADP
tissues. The red column was defined as over-expression. (C) Difference in exp
tissues. The statistical differences between the two groups were analyzed by
patients at advanced pathological stages; one-way ANOVA analysis was perfo
significantly higher in samples with larger tumor size and lymph node metast
using unpaired Student’s t-test. *P < 0.05, **P < 0.01.to GAPDH. All the four ESCC cell lines expressed
higher MALAT1 than the normal cell line, especially in
EC109 and KYSE150 (Figure 1A).
The results from tissues showed that MALAT1 was
up-regulated in 46.3% (25/54, Figure 1B) of ESCC tissues
(cancer/normal ratio > 1.5), with the mean expression level
of 4.53 in tumors and 3.02 in their counterparts (p = 0.02,
Figure 1C). Furthermore, correlation analysis of MALAT1
expression with clinicopathological parameters revealedd by qRT-PCR and its clinical significance. (A) Expression level of
red with that of the normal epithelial cell line Het-1A, data was
f MALAT1 was detected in 46.2% of ESCC tissues. Relative expression of
H; Data was presented as fold-change in tumor tissues relative to normal
ression levels of MALAT1 between cancerous and normal esophageal
paired Student’s t-test. (D) MALAT1 expression was significantly higher in
rmed to calculate the statistical difference. (E, F) MALAT1 expression was
asis. The statistical differences between the two groups were analyzed
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stage but not early-stage tumor tissues (Figure 1D), which
indicated that MALAT1 may play its oncogenic role
mostly in ESCC with advancing progression but not in the
initial phase. Additionally, we found a positive association
of MALAT1 expression with tumor size and lymph nodes
metastasis (Figure 1E and F).
We next classified the 54 ESCC patients into two groups
according to MALAT1 expression level (over-expression
or not). Clinical pathologic factors were compared be-
tween the two groups (Table 1). The over-expression
group was correlated with larger tumor size (P = 0.014)
and lymph nodes metastasis (P < 0.01). However, the rela-
tive MALAT1 expression level was not associated
with other parameters such as gender (P = 0.651), age
(P = 0.984), nor tumor differentiation (P = 0.991).
Knock down of MALAT1 in ESCC cells decreased cell
growth in vitro and in vivo
Due to the abnormal expression of MALAT1 in ESCC
cell lines and tissues, we speculated that it might have
some potential roles in ESCC progression. To assess the
role of MALAT1 in ESCC growth, we first silenced
MALAT1 expression in EC109 and EC9706 by small
interfering RNA. The siRNA which decreased MALAT1
expression level by more than 70% was chosen for fur-
ther experiments. Of these two siRNAs, siRNA1 was
chosen for further assays of EC109 while siRNA2 was
selected for EC9706 (Figure 2A).
CCK8 assays revealed that cell growth was suppressed
in both cell lines transfected with siRNAs compared
with negative control (Figure 2B), colony-formation abil-
ity was also reduced by MALAT1 silencing in EC9706
and EC109 cells (Figure 2C). The inhibitory effect of












Maxium diameter ≤4.0 cm 1
>4.0 cm 1
aChi-squared test results.
bSignificant difference.observed in a nude mice tumor growth model. Growth
of tumors from the MALAT1-depleted xenografts was
significantly inhibited compared with the control group
(Figure 2D and E).
Knockdown of MALAT1 impaired cell migration and
invasion
We investigated cancer cells migratory and invasive cap-
acity through transwell assays. Compared with control
groups, MALAT1-deficient cells displayed impeded mi-
gration in both EC109 and EC9706 cells. The migration
decreased by approximately 38.2% and 25.6% respect-
ively (Figure 3A). Similarly, invasion of EC109 and
EC9706 cells was reduced by 34.2% and 39.8% separately
following silencing of MALAT1 (Figure 3B).
Knockdown of MALAT1 induced cell cycle arrest by
activation of the ATM-CHK2 pathway
Given that MALAT1 obviously promotes ESCC cell
growth in vitro and in vivo, we next determined whether
MALAT1 has any impact on cell cycle and apoptosis. In
both cell lines, a significantly increased proportion of G2/
M phase cells were observed among MALAT1 knockdown
cells compared with that of control groups (Figure 4A).
The apoptotic rate of EC109 and EC9706 cells transfected
with siRNAs was also elevated (Figure 4B).
Further exploration of the possible mechanisms in-
volved in the cell cycle arrest was performed by Western-
blotting. For G2/M arrest is usually induced by increased
DNA damage or genome instability, we proposed that the
pathway responding to chromosome lesions may be acti-
vated by MALAT1 depletion. The results showed that
the expression level of phosphorylated ATM, CHK2,
CDC25C, and CDK1 were significantly increased upon
MALAT1 depletion, while no detectable differencesathological parameters of ESCC
xpression pattern
on-overexpression Overexpression p-valuea











Figure 2 Knockdown of MALAT1 inhibits esophageal cancer cells growth in vitro and in vivo. (A) Expression level of MALAT1 in ESCC cell
lines following treatment with si-MALAT1 or si-NC. si1 and si2 indicate the two small interfering RNA used in this study. (B) Knockdown of
MALAT1 suppressed ESCC growth in vitro. CCK8 assays were performed to determine the proliferation of ESCC cells transfected with siMALAT1
and si-NC. (C) Colony-forming growth assays were also performed to determine the proliferation of EC109 and EC9706 cells. The colonies were
counted and captured. (D) Representative image of tumor growth on nude mice. (E) Effects of MALAT1 knockdown on tumor growth in vivo,
tumors developed from si-MALAT1 stably transfected EC109 cells showed smaller tumor volume and weights. *0.05, **P < 0.01.
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CDK1 (Figure 4C). These data suggested that inhibition
of MALAT1 may activate the ATM-CHK2 pathway,
and eventually lead to G2/M arrest.
Then we detected the phosphorylated forms of ATM
and CHK2 in five pairs of tissues, and the results showed
that the phosphorylaion of ATM and CHK2 is increased
in tumor tissues (Figure 5A), suggesting that the DNA
damage events may actually occur in ESCC tissues,
which can activate the ATM-CHK2 pathway and prevent
tumor cells from growing too quickly.
To further confirm the association between MALAT1
and the ATM-CHK2 pathway, we examined the phos-
phorylated forms of ATM, CHK2, CDC25C, and CDK1
in ten ESCC tissues. Samples with high MALAT1 level
(> mean value, and over-expressed in ESCC) showed
relatively lower levels of ATM-CHK2 pathway phosphor-
ylation (Figure 5B), suggesting a negative correlation be-
tween MALAT1 expression and phosphorylation of the
ATM-CHK2 pathway in ESCC tissues, which is consistentwith results from cell lines. Together these data suggested
that high expression of MALAT1 promotes ESCC prolif-
eration by dephosphorylation of the ATM-CHK2 pathway,
which may release cells from G2/M arrest, resulting in
uncontrolled cell cycle and tumor growth.
Amplification of MALAT1 in tumor tissues may partially
contribute to its over-expression
To explore the underlying mechanisms contributing to
MALAT1 up-regulation in ESCC tissues, we first investi-
gated the methylation status of the CpG island at the
MALAT1 promoter in ten paired tissues by bisulfite se-
quencing. We sequenced the site of the 269 bp-430 bp
of the CpG island, and the results revealed the total hy-
pomethylation rate in both tumor and normal tissues,
with the average frequency of methylation merely 4.4%
in normal tissues and 4.7% in ESCC tissues (Figure 6A
and B). We then treated EC109 and EC9706 cells with
DNA demethylase agent (5-aza-CdR), and the results
showed that CDH1 was up-regulated in agent treated
Figure 3 Inhibition of MALAT1 impaired invasive and migratory capacity of esophageal cancer cells. Representative images of the
transwell migration (A) and invasion (B) assays, the bar chart represented the number of cells migrated or invaded into the lower chambers;
Magnification: 100×. *P < 0.05, **P < 0.01.
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ive. However, MALAT1 expression was not significantly
changed in demethylase treated cells (Figure 6C). These
data supported the idea that there were no obvious effects
of CpG island methylation status on MALAT1 expression.
We next detected the copy number of MALAT1 in
the 54 tumor tissues by AccuCopy™, for MALAT1 is lo-
cated on human chromosome 11q13, which is reported
to be frequently amplified in ESCC tissues. Amplification
of MALAT1 was found in 12 tumor tissues (Figure 6D),
among which nine showed increased MALAT1 expres-
sion over their counterparts (Figure 6E), while lack of
over-expression in tumor tissues without amplification
was observed in 48.1% of the cases, suggesting signifi-
cant correlation between MALAT1 over-expression and
its amplification (Table 2). These results indicated that
up-regulation of MALAT1 observed in ESCC tissues
might be partially due to amplification of the MALAT1
genomic region.No association of germline copy number variation with
somatic copy number amplification or ESCC risk was
found in the case–control study
According to Database of Genomic Variation, both
germline copy number gains and losses within the
MALAT1 locus were recurrently identified by multiple
research groups (Additional file 4: Figure S1A). Here
we detected whether the germline copy number vari-
ation of MALAT1 may lead to tissue copy number
amplification and is associated with ESCC risk in a
case–control study, which contained blood samples
from the 54 patients mentioned above. The probe for
MALAT1 copy number detection was designed to over-
lap with the recorded CNV Variation_65973 within the
MALAT1 genominc region (Additional file 4: Figure
S1A). Finally we found no germline copy number gain
in whole samples while copy number loss in twelve pa-
tients and eight controls (Additional file 4: Figure S1B),
suggesting that the amplification in tissues may not
Figure 4 Effects of MALAT1 depletion on cell cycle and apoptosis reflected by flow cytometry and the possible mechanism for cell
cycle arrest. (A) Representative images of cell cycle distribution, the bar chart represented the percentage of cells in G0/G1, S, or G2/M phases,
as indicated. (B) Representative images of cell apoptosis determined by flow cytometry analysis, the bar chart represented the sum percentage of
early and late apoptotic cells. (C) Western-blotting analysis of the ATM-CHK2 pathway in EC109 and EC9706 cells; The phosphorylated forms of
ATM, CHK2, CDC25C, and CDK1 were up-regulated upon MALAT1 knockdown, while the total amounts of these proteins exhibited no detectable
changes. (D) The putative mechanism of MALAT1 knockdown induced cell cycle arrest in G2/M on human esophageal cancer cells. ATM is
activated by phosphorylation upon MALAT1 knockdown. This activation possibly increases the level of P-CHK2 by phosphorylation at Thr68 of CHK2,
while the activated P-CHK2 further inactivates CDC25C by phosphorylation at Ser216 of CDC25C. As a result, the dephosphorylation capacity of
P-CDC25C on P-CDK1 (Tyr15) is inhibited, so the inactivated form of CDK1 accumulates, which contributes to G2/M phase arrest. (+): activation, (−):
inactivation. *P < 0.05, **P < 0.01.
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should not be a risk indicator for ESCC (Table 3).
Discussion
Roles of lncRNAs in carcinogenesis have attracted more
attention than ever before, as recent studies have found
that lncRNAs are closely associated with tumor growth,
epithelial-mesenchymal transition, and metastasis. How-
ever, little is known about their roles in ESCC. Previously
researchers have discovered that the lncRNAs HOTAIR,
POU3F3 and SPRY4-IT1 promoted ESCC progression
and may be used as prognostic biomarkers, suggesting the
critical roles of lncRNAs in ESCC [26-28].
Among these emerging functional stars, MALAT1 has
been widely accepted as a key regulator in development
and carcinogenesis, which participates in biological events
through various mechanisms, such as chromosome modi-
fication [13], mediating mRNA relocation [29], and alter-
native splicing [15,17,30]. Recent studies have confirmed
its oncogenic role in multiple cancer types, such as blad-
der, breast, and prostate cancers [31-33]. However, nostudies on how it functions in human ESCC have been
performed until now. Here we characterized its roles in
ESCC for the first time.
First, we measured the expression level of MALAT1
in cell lines and clinical tissues by qRT-PCR. Over-
expression of MALAT1 was found in 46.3% of ESCC tis-
sues, mostly in advanced tumor tissues with larger tumor
size and lymph nodes metastasis, indicating that MALAT1
may primarily participate in ESCC advancing but not
initialization, which may be a promising biomarker for
late-stage ESCC with metastasis. Inhibition of MALAT1
suppressed tumor growth in vitro and in vivo, as well as
cell migratory and invasive capacity, confirming its onco-
genic roles in ESCC.
Further results suggested that knockdown of MALAT1
inhibited ESCC cell proliferation by inducing G2/M stage
arrest and increasing the apoptosis ratio. The role of
MALAT1 in G2/M transition regulation has been previ-
ously recognized, but the underlying mechanisms remain
largely elusive. Yang et al. hypothesized that MALAT1
interacted with nuclear protein hnRNP C and facilitated
Figure 5 The phosphorylaion of ATM-CHK2 pathway in tissues
reflected by Western-blotting. (A) Phosphorylaion forms of ATM
and CHK2 in five pairs of cancerous and normal tissues; N: Normal
tissues; T: Tumor tissues. (B) Phosphorylaion of ATM-CHK2 pathway
in MALAT1 high-expression and low-expression groups.
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thereby regulating the progression of the cell cycle through
hnRNP C. Meanwhile, Tripathi et al. reported that
MALAT1-depleted cells displayed reduced expression of
B-MYB, an oncogenic transcriptional factor involved in
G2/M progression, resulting in cell cycle arrest [17]. Tri-
pathi et al. also found increased DNA damage occurred in
MALAT1 depleted cells, which should be a triggering sig-
nal for G2/M arrest. DNA damage is a common event
which occurs in tumor progression, induced by both the
tumor microenvironment and genomic instability. The
ATM-CHK2 pathway is an important component of cell
cycle regulation, which responds to DNA damage signals,
and prevents tumors growing too fast by arresting cell
cycle in G2/M stage [34]. Here we found inactivation of
ATM-CHK2 pathway by MALAT1 over-expression for the
first time.
Results from Western-blotting showed that the phos-
phorylated forms of ATM, CHK2, CDC25C, and CDK1
were upregulated upon MALAT1 knockdown. As we
know, ATM is a key regulator in cell cycle moderating,
which may be phosphorylated at Ser1981 in response to
environmental disturbance and genome instability, suchas toxicant-induced or spontaneous DNA damage [35-37].
The phosphorylated form of ATM could subsequently ac-
tivate CHK2 by phosphorylating CHK2 at the Thr68 site
[38], and the activated CHK2 played its role in suppress-
ing CDC25C by phosphorylation on Ser216 of CDC25C
[39]. The CDC25C was a phosphatase which can direct
dephosphorylation of P-CDK1 (Thr14, Tyr15) and triggers
entry into mitosis. When phosphorylated, the P-CDC25C
showed a reduced ability to dephosphorylate P-CDK1,
which was reported to be an inactive form of CDK1, pre-
venting cell cycle progression [40]. As a result, P-CDK1
accumulation occurred and the cell cycle was arrested in
G2/M (Figure 4D).
Results from ESCC tissues further supported the idea
that MALAT1 promotes tumor growth by inactivating the
cell cycle checkpoint. In ESCC tissues, MALAT1 expres-
sion was negatively associated with phosphorylation of
the ATM-CHK2 pathway, suggesting over-expression of
MALAT1 may contribute to rapid tumor growth by sup-
pressing cell cycle arrest. In total, our results highlighted
the importance of MALAT1 in ATM-CHK2 pathway
regulation, which may help us to interpret the mecha-
nisms on how MALAT1 regulates tumor growth from a
new perspective. However, more detailed information
about the association between MALAT1 expression and
ATM-CHK2 pathway is still required.
Although over-expression of MALAT1 has been re-
ported in multiple cancer types, little is known about the
factors which contribute to its up-regulation. Here we
sought to explore the uncharted factors contributing to
its up-regulation. Methylation of the CpG island in the
promoter may be a crucial mechanism in regulating
gene expression on an epigenetic level [41]. By computa-
tionally screening the promoter of MALAT1, we found a
CpG island which is 441 bp long. As no previous studies
revealed whether this CpG island was associated with
MALAT1 expression, we checked the correlation be-
tween the methylation status of the CpG island and
MALAT1 expression level by bisulfite sequencing. The
total methylation rate in both groups were extremely
low and showed no apparent differences, indicating that
the methylation status of MALAT1 promoter may not
be a major factor contributing to its deregulation. No
obvious changes in MALAT1 expression level upon
treatment of ESCC cells with demethylase 5-aza-cdR
further supported this idea.
MALAT1 is located on 11q13 of the human genome,
which has been verified to be frequently amplified in
ESCC tissues [42,43], and recent studies have discovered
the tight correlation between lncRNAs amplification
with their expression level [44,45], we then detected the
genomic copy number of MALAT1 in the 54 tumor tis-
sues mentioned above by a newly developed method
AccuCopy™, which has been applied in other excellent
Figure 6 Effects of CpG island methylation status and copy number amplification on MALAT1 expression level. (A) Methylation status of
the CpG island in a representative pair of clinical tissues, assessed by bisulfite sequencing. Open and filled squares denote un-methylated and
methylated CpG sites respectively; each row represents a single clone. (B) No obvious difference in CpG island methylation frequency was
observed in the ten pairs of tissues. A paired Student’s t-test was performed to determine the statistical significance. (C) The expression level
of MALAT1 and CDH1 in EC109 and EC9706 cells following treatment with demethylase agent 5-aza-cdR (0, 5, and 10 μM). (D) Genomic copy
number of MALAT1 in tumor tissues calculated by AccuCopy™ system. Red bars represented samples with MALAT1 amplification in tumor
tissues. (E) Relative expression level of MALAT1 (normalized to GAPDH) in the twelve pairs of tissues, which showed gene amplification in
tumor tissues. *P < 0.05, **P < 0.01.
Hu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:7 Page 11 of 13works, and proven to be efficient and accurate [25,46]. The
results showed that amplification of MALAT1 was found
in 12 ESCC tissues, among which nine showed an over-
expression pattern, implicating that the up-regulation of
MALAT1 in tumor tissues may partially be attributed to
copy number amplification in somatic tissues.
As amplification of MALAT1 was found in ESCC tis-
sues, then we wondered how the amplification in tumor
tissues occurred. Previous studies have proclaimed that
the germline copy number variation may be an importantTable 2 Association between MALAT1 amplification and its o
Copy number status in tumor tissues Amplification
Non-amplification
aFisher’s exact test.
bSignificant difference.source of somatic genome abnormality [46,47], and germ-
line copy number gains across MALAT1 have been re-
ported by other groups [48,49]. We therefore tested if this
association also existed in the MALAT1 region. In this
study, we genotyped the copy number of MALAT1 in 201
ESCC patients (the 54 patients mentioned above included)
and 193 healthy controls. Surprisingly, we found no copy
number gain in germline samples, indicating that the
CNV status may differ in diverse ethnic groups, and it is
hard to predict whether the amplification of MALAT1 inver-expression in ESCC tissues




Table 3 No association of germline copy number variation with ESCC risk was found in the case–control study
genotypes No. of cases No. of controls Crude OR (95%CI) p-value Adjusted OR (95%CI)b p-value
+/+a 189 185 1.00 (reference) 1.00 (reference)
+/−a 12 8 1.437 (0.574–3.596) 0.438 1.385 (0.544–3.522) 0.494
aGenotypes: +/+, wild-type; +/−, hemizygous deletion.
bAdjusted by gender, age and smoking status.
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that the amplification of MALAT1 in ESCC tissues may be
a complicated event arising during the progression phase of
ESCC, but not being simply derived from germline origin.
Moreover, we did not find any frequency discrepancy of
germline copy number loss between the cases and controls
groups, indicating that the germline copy number variation
on MALAT1 should not be treated as an ESCC susceptibil-
ity indicator, in spite of its significant role in ESCC.
Conclusions
Together these findings indicate that MALAT1 is a
player of great importance in ESCC. It may promote
ESCC growth by moderating the ATM-CHK2 pathway
which is involved in cell cycle orchestrating, and the
amplification of MALAT1 may be an important cause
for its up-regulation in ESCC tissues. However, much
more work is still required to determine the detailed
mechanisms it functions in ESCC and the potentiality of
MALAT1 as a therapeutic target for ESCC.
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